KARUNA THERAPEUTICS INC (KRTX) Stock Price & Overview
NASDAQ:KRTX • US48576A1007
Current stock price
The current stock price of KRTX is 329.83 USD. Today KRTX is up by 0.03%. In the past month the price increased by 3.27%. In the past year, price increased by 72.12%.
KRTX Key Statistics
- Market Cap
- 12.583B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.72
- Dividend Yield
- N/A
KRTX Stock Performance
KRTX Stock Chart
KRTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KRTX. When comparing the yearly performance of all stocks, KRTX is one of the better performing stocks in the market, outperforming 94.34% of all stocks.
KRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRTX. KRTX has a great financial health rating, but its profitability evaluates not so good.
KRTX Earnings
KRTX Forecast & Estimates
23 analysts have analysed KRTX and the average price target is 329.12 USD. This implies a price decrease of -0.22% is expected in the next year compared to the current price of 329.83.
For the next year, analysts expect an EPS growth of -5.2% and a revenue growth 1701.02% for KRTX
KRTX Groups
Sector & Classification
KRTX Financial Highlights
Over the last trailing twelve months KRTX reported a non-GAAP Earnings per Share(EPS) of -11.72. The EPS decreased by -34.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.46% | ||
| ROE | -34.58% | ||
| Debt/Equity | 0 |
KRTX Ownership
KRTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 351.47B | ||
| AMGN | AMGEN INC | 15.09 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.44 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.23 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KRTX
Company Profile
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2019-06-28. The firm creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The firm is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The firm is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
Company Info
IPO: 2019-06-28
KARUNA THERAPEUTICS INC
99 High Street, 26th Floor
Boston MASSACHUSETTS 02110 US
CEO: Steven Paul
Employees: 210
Phone: 18574492244
KARUNA THERAPEUTICS INC / KRTX FAQ
What does KARUNA THERAPEUTICS INC do?
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2019-06-28. The firm creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The firm is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The firm is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
Can you provide the latest stock price for KARUNA THERAPEUTICS INC?
The current stock price of KRTX is 329.83 USD. The price increased by 0.03% in the last trading session.
Does KARUNA THERAPEUTICS INC pay dividends?
KRTX does not pay a dividend.
What is the ChartMill rating of KARUNA THERAPEUTICS INC stock?
KRTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of KRTX stock?
KARUNA THERAPEUTICS INC (KRTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for KARUNA THERAPEUTICS INC?
The Revenue of KARUNA THERAPEUTICS INC (KRTX) is expected to grow by 1701.02% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.